Why Advisory Committees Remain Essential in an Era of Complex Medicines

Last month, a senior FDA official dismissed advisory committees (AdComs) as "costly," "slow," and defined by "pomp and flash." The unnamed official suggested that the pharmaceutical industry uses "slick presentations" to obscure facts and cast doubt on the integrity of the independent panelists themselves. Having spent the past 25 years working alongside scientists, statisticians, and clinicians preparing programs for health authority review, with the explicit aim of bringing safe, effective treatments to patients, I respectfully but strongly disagree.

Navigating complexity to find value

Modern drug development is rarely black and white. We are seeing increasingly complex therapies, especially for rare diseases, where traditional endpoints may be harder to define.

In these gray areas, an advisory committee can be essential; it allows for a real-time debate on the benefit-risk profile that a written application simply cannot capture. If a sponsor arrives with muddled messaging, the meeting fails everyone.

Preparation ensures that the "totality of the evidence" is communicated clearly. This clarity allows the experts to focus on science rather than struggling to decipher the charts. Ultimately, this ensures that a potentially life-changing therapy isn't rejected simply because its value was poorly explained.

Defining "right" through the patient lens

Perhaps most importantly, a committee is often the only opportunity to hear directly from patients — the population that both sponsors and the FDA seek to support.

Determining the "right" treatment requires an understanding of what is meaningful to a patient. For diseases with high unmet needs, a statistical improvement that looks marginal on paper may be life-altering in practice. Committees provide a vital platform for "open public hearing strategies," where these nuances are debated openly. Without this forum, we risk a regulatory environment that prioritizes p-values over impact on patients.

The current system has limitations

Strict conflict-of-interest rules have sometimes created selection bias regarding panelists, occasionally limiting the pool of available hyper-specialists. The system is not perfect.

However, the suggestion that these experts are "political" or unskilled is fundamentally untrue. Committee members bridge the gap in specialization that no single agency can cover. By subjecting data to external, peer-reviewed scrutiny, committees help the FDA distinguish between a failed experiment and a genuine breakthrough.

Dismissing this role weakens the review process. Preparing to engage with these experts isn't about “theater”; it is about ensuring data are robust enough to withstand the debate required to bring the right treatments to patients.

Science-centric

I share and vigorously support the FDA’s goal: ensuring the right treatments reach patients based on evidence.

In a complex regulatory environment, clarity is a shared necessity. Ultimately, the committee process isn't about winning a risk-benefit debate. It is about removing the friction between a potential cure and the people who need it. When a well-prepared team steps up to the podium, they ensure that a life-changing therapy is judged strictly on its scientific merits. That is a service to the future of medicine.

Katie McCarthy is senior vice president, clinical and regulatory, at Lumanity.